leadf
logo-loader

Week Ahead: Summit Therapeutics to reflect on year of unrelenting progress

News flow for the drugs developer has been nothing but positive this year

Man in wheelchair
News from Summit has come thick and fast this year

Drugs developer Summit Therapeutics has put out so many updates this year, it is hard to know what else it could include that is new in Tuesday's results.

As a pre-revenue company, the figures will be largely irrelevant, though of course the cash burn will be of interest, as it is with all early stage biopharmaceuticals companies.

What investors will really want to see are signs of how quickly the company is progressing towards the “inflection point” chief executive officer Glyn Edwards was talking about last November.

The company has two main programmes on the go: one for the treatment of Duchenne muscular dystrophy (DMD), a fatal muscle wasting disease that mainly affects boys; and the other is an antibiotic to combat hospital superbug C.Diff.

News flow on both programmes has been nothing but positive this year.

Last month, the C.Diff candidate (ridinilazole) got a boost as the US patent and trademark office granted a "composition of matter" patent. It gives a period of exclusivity for in the United States until at least December 1, 2029, with the possibility of it being extended.

A few days before that announcement, the company revealed the US Food and Drug Administration had allowed the company to broaden the scope of its phase II clinical trial of its drug ezutromid to trial sites in the US.


Significant announcements expected

Monday

Finals: Beximco Pharmaceuticals Ltd (LON:BXP),

Interims: ITE Group PLC (LON:ITE), Premier Veterinary Group PLC (LON:PVG), Telecom Egypt (LON:TEEG)

Trading statements: Dignity PLC (LON:DTY)

Tuesday

Finals: Maxcyte Inc (LON:MXCT), Quantum Pharma PLC (LON:QP.), Summit Therapeutics (LON:SUMM)

Interims: Cambria Automobiles PLC (LON:CAMB), easyJet PLC (LON:EZJ)

Trading statements: The Capita Group PLC (LON:CPI), Hiscox Ltd (LON:HSX)

Wednesday

Finals: C&C Group PLC (LON:CCR), Experian PLC (LON:EXPN), Vertu Motors PLC (LON:VTU)

Interims: Arrow Global Group (LON:ARW), Compass Group PLC (LON:CPG), TUI AG (LON:TUI)

Trading statements: John Wood Group PLC (LON:WG.), National Express Group PLC (LON:NEX), Premier Oil PLC (LON:PMO), Purplebricks Group PLC (LON:PURP), Renishaw PLC (LON:RSW)

Thursday

Finals: JZ Capital Partners Ltd (LON:JZCP), Talktalk Telecom Group PLC (LON:TALK), Vedanta Resources PLC (LON:VED)

Interims: Coca-Cola HBC (LON:CCH), Vedanta Resources PLC (LON:VED)

Trading statements: Cairn Energy PLC (LON:CNE), ITV PLC (LON:ITV), Mondi Plc (LON:MNDI), Old Mutual Group PLC (LON:OML), The Rank Group PLC (LON:RNK), Vesuvius (LON:VSVS)

Friday

Interims: New Europe Property Investments plc (LON:NEPI)

Trading statements: Coca-Cola HBC (LON:CCH)

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell's Paul Anderson hails FDA approval for dental bone and tissue...

Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive's Andrew Scott soon after announcing they've received Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US....

20 hours, 28 minutes ago

3 min read